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The complex of cathepsin L and the fragment of the MHC class II-associated invariant chain was purified from human kidney. M, of the complex, 
as determined by gel filtration, is about 40,000. Both components were identified by amino acid and sequence analyses. The bound invariant chain 
fragment is almost identical to the additional segment found in p41, but not in the p3 1 form of the invariant chain. The complex has significantly 
enhanced stability at neutral and slightly alkaline pH, and reduced proteolytic activity against he synthetic substrate Z-Phe-Arg-MCA compared 
to free cathepsin L. The complex exhibits no enzymatic activity against he protein substrate azocasein. For the first time, the invariant chain was 
found in a complex with a protein, which was not an MHC molecule. 
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1. INTRODUCTION 
Cathepsin L (EC 3.4.22.15) is known to be the most 
powerful lysosomal cysteine proteinase. It belongs to 
the papain superfamily and plays an important role in 
the degradation of intracellular proteins [l]. It degrades 
a variety of protein substrates, such as collagen, elastin, 
insulin and glucagon, with much higher specific activity 
than the other lysosomal proteinases [2,3]. Cathepsin L 
is routinely assayed with azocasein in the presence of 
urea, and with the synthetic substrate Z-Phe-Arg-MCA 
[2]. Its activity and stability are highest in slightly acidic 
media [4]. At neutral and alkaline pH, it is rapidly inac- 
tivated [4-6]. The most potent physiological regulators 
of cathepsin L are inhibitors from the cystatin superfa- 
mily [7]. 
Cathepsin L has been purified from many organisms, 
such as bovine [8,9], chicken [lo], rat [ll], rabbit [12] 
and human [4,6,13]. The species variants share similar 
properties. In human, it is expressed at the highest level 
in liver, lungs and kidney; its level in other tissues is 
lower [14]. 
Lysosomal proteinases participate in many biological 
processes. One of them is antigen recognition by the 
MHC class II-restricted T lymphocytes, which requires 
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two, still poorly understood, proteolytic events: prote- 
olytic degradation of the MHC class II-associated in- 
variant chain (Ii) and processing of protein antigens 
[15]. Although there have been attempts to clarify the 
identity and the precise location of the responsible en- 
zyme(s), not much is yet known about i [16-211. 
Here we report for the first time purification of the 
complex of cathepsin L and the fragment of the MHC 
class II-associated invariant chain. The amino-terminal 
sequence of the bound fragment was determined, and 
its stabilizing and inhibitory effect on cathepsin L is 
shown. 
2. MATERIALS AND METHODS 
2.1. Materials 
Cm-Sephadex C-50, Sephacryl S-200, DEAE-Sephacel, Mono Q 
anion-exchange column and PhastGel Separation Media were pur- 
chased from Pharmacia (Sweden). Z-Phe-Arg-MCA and Protein Mo- 
lecular Weight Standards used for calibration of the gel filtration 
column were from Serva (Germany). ChromSpher C8 column was 
from ChromPack (Netherlands). Sequencing reagents were obtained 
from Applied Biosystems (USA). All other chemicals used were of 
analytical grade. 
2.2. Purification procedure 
The cathepsin LB complex was purified from human kidneys using 
a method mod&d from that previously described for the purification 
of cathepsin L [6]. Frozen kidneys were thawed, cut into pieces and 
homogenized in 2 vol. of 0.1 M sodium acetate buffer, pH 5.0, contain- 
ing 0.3 M NaCl, 1 mM EDTA and 0.2% Triton X-100. Insoluble 
material was removed by centrifugation (10,800 x g, 20 min), and the 
supematant was adjusted to pH 4.2 and incubated at 37°C for 4 h. 
After the removal of precipitated proteins by centrifugation, the super- 
natant was precipitated with solid ammonium sulfate up to 75% satu- 
ration at 0°C. The precipitate was resuspended in 20 mM sodium 
acetate buffer, pH 5.2, containing 1 mM EDTA, and insoluble mate- 
rial was removed by centrifugation. The supematant was applied to 
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a Cm-Sephadex C-50 column (4 x 37.5 cm), equilibrated with the same 
buffer. The column was washed with three bed volumes of the buffer, 
and bound proteins were eluted with a linear gradient of NaCl (O-l .O 
M) in the same buffer. Fractions contain~g the complex (at 0.6 M 
NaCl) were pooled, dialysed against 0.1 M sodium acetate buffer, 
containing 0.3 M NaCl and 1 mM EDTA, pH 5.0, and concentrated. 
The concentrate was applied to a Sephacryl S-200 column (3 x 140 
cm), equilibrated with the same buffer. Collected fractions were as- 
sayed using Z-Phe-Arg-MCA as a substrate, as described previously 
[22]. Active fractions in the 2545 kDa range were pooled, dialysed 
against 20 mM piperazine buffer, confining 1 mM EDTA, pH 5.5. 
The sample was applied to a DEAE-Sephacel column (1.7 x 25 cm), 
equilibrated with the same buffer. The column was washed, and bound 
proteins were eluted with a W.3 M NaCl linear gradient in the 
starting buffer. Fractions, active on Z-Phe-Arg-MCA at pH 7.5 
(cathepsin LIi complex), were eluted at 0.12 M NaCl, while fractions, 
active on the same substrate at pH 5.5 (free cathepsin L), were eluted 
at 0.24 M NaCl. Fractions, containing the complex, were combined, 
concentrated and dialysed against 20 mM bis-tris buffer, containing 
1 mM EDTA, pH 6.2, and then chromatographed on a Mono Q 
column of a Pharmacia FPLC system, equilibrated with the same 
buffer. A linear gradient of NaCl (o-0.1 M) in the starting buffer was 
used for the elution of bound proteins. The complex was eluted at 0.05 
M NaCl. 
2.3. HPLC 
The complex, eluted from the Mono Q column, was analysed by 
HPLC (Milton Roy LCD, UK) on a ChromSpher C8 column (3 x 100 
mm), equilibrated with 0.1% trifluoroacetic acid. Bound proteins were 
eluted with a linear gradient of acetonitrile (670%) in the starting 
solution. Absorbance was monitored continuously at 215 nm. 
2.4. Enzyme assays 
The complex was assayed with Z-Phe-Arg-MCA at pH 7.5 as de- 
scribed for cathepsin S [22]. Assays with the same substrate at pH 5.5 
were also performed [2]. 
2.5. SDS-PAGE and isoelectric focusing 
Electrophoretic separations were performed using PhastSystem 
(Pharmacia, Sweden), following the instructions of the manufact~er. 
Either S-25% gradient polyacrylamide gels (0.45 x 43 x 50 mm) with 
molecular weight markers ranging from A& 14,400 to 94,000 (Pharma- 
cia) or 20% homogeneous polyacryramide gels (0.45 x 43 x 50 mm) 
together with low molecular weight markers (M, from 2,500 to 16,950) 
(LKB) were used for SDS-PAGE, while PhastGel IEF 3-9 slabs 
(0.35 x 43 x 50 mm) were used for isoelectric focusing. 
2.6. M, determination by gei filtration 
A column of Sephacryl S-208 (8 x 1,050 mm) was equilibrated with 
0.1 M sodium acetate buffer, pH 5.0, containing 0.3 M NaCl and 1 
mM EDTA, and calibrated with Dextran blue, rabbit muscle aldolase, 
egg albumin, chymotrypsinogen and cytochrome c. The purified com- 
plex was applied to the column in a volume of 700 yl, and protein 
~n~entrations in eluted fractions (1 ml) were measured at 280 nm. 
2.1. Continuous measurement of proteolytic activity of the complex 
The complex was preactivated at 37°C for 5 min in 5 mM DTE in 
0.3 M sodium acetate buffer, pH 5.7, containing 1 mM EDTA. Buffers 
of various pH values, ranging from pH 3.0 to 8.0, were prepared by 
mixing 0.1 M citric acid and 0.2 M Na,HPO,, They also contained 1 
M NaCl and 1 mM EDTA. The activity of the complex against 
Z-Phe-Arg-MCA was measured at room temperature, at pH values in 
0.5 unit intervals. The reaction was started by the addition of 0.250 
ml of the preactivated complex (2 nM final concentration) to 2.750 ml 
of Z-Phe-Arg-MCA (5 PM final concentration) in the appropriate 
buffer. The product formation was continuously followed by measur- 
ing fluorescence at excitation and emission wavelengths of 370 and 460 
nm, respectively. Progress curves were recorded using a Perkin Elmer 
LS-3 sp~tro~uo~meter connected to an IBM-XT microcomputer. 
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Flusys software [23] was used for computer control of the spec- 
trofluorimeter. 
2.8. Amino acid and sequence ~~ys~~ 
Amino acid composition was analysed by Applied Biosystems 
(USA) 421 Amino Acid Analyser, with pre-cohnnn derivatization with 
phenylisothiocyanate. 
Automated sequence analyses were performed on Applied Biosys- 
terns liquid phase sequenator model 475A, connected on-line to a 
120A phenylthiohyd~toin-amino acid analyzer from the same manu- 
facturer. 
3. RESULTS AND DISCUSSION 
The cathepsin L-Ii complex, as well as free cathepsin 
L, were detected in human kidney. The two forms of the 
enzyme were separated on DEAE-Sepha~l at pH 5.5. 
The elution profile is shown in Fig. 1. The complex was 
recognized by high activity against Z-Phe-Arg-MCA at 
pH 7.5, while cathepsin L had no activity under the 
assay conditions. On the other hand, free cathepsin L 
exhibited much higher activity than its counterpart in 
the complex at pH 5.5. Moreover, the complex was not 
active against he protein substrate azocasein, using the 
standard assay for cathepsin L [2]. These were the first 
indications for the potential stabilizing and inhibitory 
role of Ii. 
The fragment of the invariant chain remained associ- 
ated with cathepsin L during the whole purification 
fluorescence 
A280 
c(NaC1) (M) 
250. 
complex 
2.5 
0 20 40 60 80 100 120 
fraction 
Fig. 1. Ion-exchange chromatography of the pooled fractions from the 
Sephacryl S-200 column on DEAE-Sephacel. Experimental conditions 
are described in Section 2. The solid line represents absorbance at 280 
nm. The dotted and the dashed lines represent activity against Z-Phe- 
Arg-MCA at pH 5.5 and 7.5, respectively. The horizontal bar indicates 
the pooled fractions. Fifty times less diluted samples were taken from 
fractions for the assay at pH 7.5 than for the assay at pH 5.5. 
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Fig. 2. Dissociation of the complex by reversed-phase HPLC. Exper- 
imental details are described in Section 2. 
procedure. It dissociated under the denaturing condi- 
tions on the ChromSpher C8 column. The elution pat- 
tern revealed the presence of two components (Fig. 2). 
The first peak represented a fragment of the p41 form 
of the MHC class II-associated invariant chain, as de- 
termined by sequence analysis. 26 amino acid residues 
on the amino-terminal end were determined, and they 
are identical to the amino-terminal part (starting with 
the second amino acid residue) of the additional frag- 
ment of p41, which is derived from the alternatively 
spliced exon [ 151, and which is not found in the p3 1 form 
of the invariant chain (Fig. 3). The amino acid compo- 
sition of the fragment bound to cathepsin L (not shown) 
is nearly identical to the amino acid composition of the 
a 
1 10 
extra fragment, unique to p41, suggesting that carboxyl- 
terminal parts probably do not differ very much either. 
The second peak was recognized as cathepsin L by its 
amino-terminal sequence. 
The complex was eluted as a single peak with M, of 
- 40,000 on the analytical Sephacryl S-200 column (not 
shown). This peak was applied to SDS-PAGE, where, 
under non-reducing conditions, it migrated predomi- 
nantly as two bands, one with M, 32,000 and the other 
with M, below 14,000, indicating complex dissociation 
(not shown). The band with M, 32,000 corresponds to 
cathepsin L, consistent with the published data [13], and 
the other band corresponds to the Ii fragment. Under 
reducing conditions, three major bands can be seen, one 
with M, - 26,000, corresponding to the heavy chain of 
cathepsin L, and two below &f, 14,000. In order to 
determine the molecular weight of these two bands, 
electrophoresis was also performed on a 20% homoge- 
neous polyacrylamide gel in the presence of low molec- 
ular weight markers (not shown). One band of protein 
appeared at M, 9,000 (Ii fragment), the other appeared 
at M, 6,000 (light chain of cathepsin L). 
On the isoelectric focusing gel, a single band with p1 
value 5.3 can be seen (Fig. 4), demonstrating the homo- 
geneity of the complex. 
In order to study the pH-dependence of the interac- 
tion of the invariant chain with cathepsin L, continuous 
measurement of the proteolytic activity of the complex 
against Z-Phe-Arg-MCA at various pH was performed. 
We tried to dissociate the complex by combining the 
effect of high substrate concentration, dilution and pH 
changes. Experimental data obtained at pH 3.5,6.5 and 
8.0 are shown in Fig. 5. The proteolytic activity of the 
complex at pH 3.0 (not shown) and 3.5 (Fig. 5a) resulted 
in an exponential release of the fluorescent product. The 
progress curve could be fitted by nonlinear regression 
analysis to the following integrated equation [24]: 
[P] = V,Z + (vi - v,)(l - eAk’)/k J%. (1) 
where [PI, Vi, v, and k represent he product concentra- 
20 26 
LTKCQEEVSHIPAVHPGSFRPKCDEN 
194 200 210 219 
b 
EF 
19.9 267 280 
Fig. 3. (a) Amino-terminal sequence of the Ii fragment bound to cathepsin L. The upper numbering starts with the first amino acid of the bound 
fragment. The lower numbering is according to p41. (b) Schematic representation of p41 form of Ii [26]. TM stands for transmembrane r gion, 
and EF for extra fragment, unique to p41. The horizontal arrow indicates the position of the determined amino-terminal part of the fragment bound 
to cathepsin L. 
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Fig. 4. Isoelectric focusing of the complex. Lanes: 1, standards; 2, 
complex. 
tion, the initial velocity, the steady-state velocity and the 
apparent first-order rate constant respectively. This 
equation describes the following situation: 
E+S= ES*E+P 
+ 
f; 
EL 
E stands for enzyme (cathepsin L), L for ligand (Ii 
fragment), S for substrate and P for product. At other 
pH values (from 4.0 to 7.9, the rate of product forma- 
tion was constant (Fig. 5b). At pH 8.0, practically no 
proteolytic activity against the substrate could be de- 
tected (Fig. 5~). After 7 min of incubation at pH 8.0, the 
reaction mixture was acidified with acetic acid to pH 
3.5. An exponential increase of fluorescence was ob- 
served, indicating that active cathepsin L had been re- 
leased from the complex. These results demonstrate that 
the fragment of the invariant chain is bound to cathep- 
sin L in a way, that it inhibits and stabilizes the enzyme. 
At pH 3.0 and 3.5 the complex dissociates, active en- 
zyme molecules are released and the product formation 
rate (the slope of the progress curve) increases. Human 
kidney cathepsin L is known to be very unstable above 
pH 5.5 [4], has a very short half life at pH 8.0 [6], and 
fluorescence 
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Fig. 5. Progress curves for the proteolytic action of the complex at 
various pH. Experimental conditions are described under section 2. 
Experimental points are marked with (+). The solid lines represent 
theoretical curves calculated using Equation 1. (a) pH 3.5, (b) pH 6.5, 
(c) initial pH was 8.0. The arrow indicates the time when the reaction 
mixture was acidi6ed to pH 3.5. 
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would be therefore completely denatured in 7 min with- 
out the possibility of restoring its activity simply by 
acidification. This is evidence that cathepsin L is 
strongly stabilized by the invariant chain. The enzyme 
assay, by which the complex was traced during the pu- 
rification procedure, was based on this assumption. The 
assay started with one hour of preincubation at pH 7.5 
and 37T. This allowed us to determine the activity of 
the complex in the presence of free cathepsin L, which 
is very unstable at neutral and alkaline pH [4,25]. In the 
complex with Ii, cathepsin L has been shown to be 
stabilized, thus enabling measurement of its activity 
even in such unfavourable conditions. Using the same 
procedure, the activities of two other cysteine pro- 
teinases, namely cathepsins J and S, could be detected. 
However, cathepsin J was separated from other cysteine 
proteinases by gel filtration, whereas the activity of 
cathepsin S in human kidney was too low to interfere 
with our measurements. 
In conclusion, cathepsin L was found in a complex 
with the invariant chain fragment, which has stabilizing 
and inhibitory effects on it. This might be of physiolog- 
ical importance in the in vivo regulation of cathepsin L 
activity. However, additional studies will be needed to 
clarify the site and the mechanism of complex forma- 
tion, and its precise role within the cell. 
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